The results suggest room for improvement in Canadian trauma systems to ensure that all children receive optimal care, ...

PRESS RELEASEAB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV HIGHLIGHTING CLINICAL BENEFIT WITH MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS ...

Trastuzumab deruxtecan continues to demonstrate superior safety and efficacy compared with trastuzumab emtansine in patients with high-risk, HER2-positive early breast cancer who have residual ...

Objective We evaluated the long-term association between the COVID-19 pandemic and the language development of children aged ...

In the CAPItello-291 trial of capivasertib plus fulvestrant, 73% of patients had already received a CDK4/6 inhibitor. As ...

So far this year, at least four states have redrawn their congressional districts with the stated goal of advantaging one party or the other in the 2026 midterms. Several others are exploring similar ...

Experts predict a test measuring p-tau217 in blood plasma may become a standard screening tool for Alzheimer’s disease in ...

Dec 12 (Reuters) - Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, ...

The FDA has cleared the initiation of a pivotal Phase 3 trial testing pridopidine in people with early, rapidly progressive ...

Tukysa, combined with Herceptin and Perjeta, extends progression-free survival in HER2+ metastatic breast cancer, showing ...

"Completing enrollment in SEAL IT is a major milestone--not only for Galaxy but for the field of neurointervention," said Dr. Sam Zaidat, President and CEO of Galaxy Therapeutics. "We designed this ...

Beacon Biosignals, a leader in AI-driven neurophysiology and precision drug development, today announced a collaboration with Harmony Biosciences (Nasdaq: HRMY), a pharmaceutical company dedicated to ...